Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BeiGene (BGNEResearch Report) and Dyne Therapeutics (DYNResearch Report) with bullish sentiments.

BeiGene (BGNE)

In a report released today, Andrew Berens from Leerink Partners maintained a Buy rating on BeiGene, with a price target of $414.00. The company’s shares closed last Wednesday at $356.41.

According to TipRanks.com, Berens is a 4-star analyst with an average return of 6.7% and a 60.8% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Deciphera Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for BeiGene with a $417.33 average price target.

See today’s best-performing stocks on TipRanks >>

Dyne Therapeutics (DYN)

Jefferies analyst Eun Yang maintained a Buy rating on Dyne Therapeutics yesterday and set a price target of $47.00. The company’s shares closed last Wednesday at $14.88, close to its 52-week low of $13.50.

According to TipRanks.com, Yang is a 4-star analyst with an average return of 7.6% and a 50.4% success rate. Yang covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Aerovate Therapeutics, and Taysha Gene Therapies.

Currently, the analyst consensus on Dyne Therapeutics is a Moderate Buy with an average price target of $40.50, representing a 173.5% upside. In a report issued on October 1, Piper Sandler also maintained a Buy rating on the stock with a $34.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.